Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00803179 · ClinicalTrials.gov registry record · Phase 1
Growth Hormone Therapy for Wasting in Cystic Fibrosis
A Phase 1 study, sponsored by University of Massachusetts, Worcester.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00803179: Clinical Trial Phase 1 study, sponsored by University of Massachusetts, Worcester.
NCT00803179 is a Phase 1 study that was terminated before completion, run by University of Massachusetts, Worcester. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00803179, a Phase 1 study, was terminated before completion, sponsored by University of Massachusetts, Worcester.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
Our hypothesis is that Growth Hormone (GH) will not only target the peripheral tissue to stimulate weight and muscle growth which will maximize nutritional potential and improve overall quality of life. We theorize that this will occur through a multitude of factors: increased appetite, more constructive utilization of caloric intake and decreased catabolic signaling. The first aim will address changes in weight and lean body mass following the institution of GH therapy in adults with Cystic Fibrosis (CF) related wasting. The second aim will measure impact on quality of life of these individuals. Additionally, the third aim will monitor effects of GH therapy on diabetes and insulin sensitivity. Finally, the fourth aim will observe changes in the subjects underlying diagnosis of CF, specifically lung function, muscle strength and inflammatory state.
Interventions
- DRUG Nutropin AQ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2008-11 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Why NCT00803179 stopped before completion
NCT00803179 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Nutropin AQ is the first listed.
NCT00803179 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00803179 about?
NCT00803179 is a clinical study titled "Growth Hormone Therapy for Wasting in Cystic Fibrosis". Our hypothesis is that Growth Hormone (GH) will not only target the peripheral tissue to stimulate weight and muscle growth which will maximize nutritional potential and improve overall quality of life. We theorize that this will occur through a multitude of factors: increased appetite, more constru...
What is the current status of trial NCT00803179?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2008-11. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00803179?
The interventions under investigation include: Nutropin AQ (DRUG).
Who is sponsoring clinical trial NCT00803179?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00803179's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia